Abbott has confirmed that a performance shift for the ARCHITECT HA V Ab-IgM, ARCHITECT HA V Ab-IgG and Alinity i HA VAb IgG reagent lots as listed in table has the potential to generate falsely elevated control and patient sample results. Preliminary investigation of this issue has identified a manufacturing error specific to the lots listed identified. Additional information will be provided upon completion of the investigation to help quantify the magnitude of the shift in results.